Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 21:9:F1000 Faculty Rev-131.
doi: 10.12688/f1000research.21981.1. eCollection 2020.

Recent advances in the treatment of pancreatic cancer

Marc T Roth  1 , Dana B Cardin  1 , Jordan D Berlin  1
Affiliations
Review

Recent advances in the treatment of pancreatic cancer

Marc T Roth et al. F1000Res. .

Abstract

Pancreatic ductal adenocarcinoma is one of the deadliest solid tumor malignancies and is projected to become a leading cause of cancer-related death in coming years. Improving quality of life and survival amongst these patients will require new ideas and novel therapies in a multidisciplinary approach. This review will cover the most recent advances in the comprehensive treatment of pancreatic cancer and place them within a historical context when necessary. Treatment of all disease stages will be discussed, but the focus is on systemic therapy as novel drugs and new treatment combinations enter the clinic. This will include more aggressive chemotherapy in earlier disease stages, approved uses for immunotherapy, and targetable mutations. In addition, negative trials of importance and controversial topics will be noted.

Keywords: pancreatic cancer; review.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

References

    1. Siegel RL, Miller KD, Jemal A, et al. : Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. 10.3322/caac.21551 - DOI - PubMed

    2. F1000 Recommendation

    1. Rahib L, Smith BD, Aizenberg R, et al. : Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21. 10.1158/0008-5472.CAN-14-0155 - DOI - PubMed
    1. Neoptolemos JP, Stocken DD, Friess H, et al. : A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–10. 10.1056/NEJMoa032295 - DOI - PubMed
    1. Oettle H, Neuhaus P, Hochhaus A, et al. : Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81. 10.1001/jama.2013.279201 - DOI - PubMed
    1. Neoptolemos JP, Palmer DH, Ghaneh P, et al. : Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24. 10.1016/S0140-6736(16)32409-6 - DOI - PubMed

    2. F1000 Recommendation

MeSH terms